Implantation is a determining step in human reproduction which requires the transition from a pro-inflammatory state to an anti-inflammatory state allowing the implantation of a competent embryo within a receptive endometrium, and then the maternal immunotolerance towards the alloantigenic fetus. Repeat implantation failures (RIFs), that refers to the fail to achieve a clinical pregnancy after the transfer of at least 3-4 good quality embryos or two blastocysts, and unexplained recurrent spontaneous miscarriage (RM) (≥2-3) could be related in some patients to immune imbalances characterized by an excessive and prolonged inflammatory response and/or a defect of anti-inflammatory regulation. In this context, several therapies have been evaluated in patients with RIFs or RMs in order to restore the immune balance, with heterogeneous results. No serum biomarker assay has been routinely approved to identify patients with immune imbalances that may explain repeated pregnancy failures and to predict the success of the subsequent IVF/ICSI cycle. The immunological analysis on peripheral blood will be based on the determination of the proportions of immune subpopulations (e.g. CD4+ et CD8+, TH1, TH2, TH17, Treg, ILC 1, ILC2, and ILC3) on the one hand and the circulating level of plasma cytokines on the other hand.
Age range
18 Years – 39 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Variation of the proportion of CD4+ subpopulations between both patient groups
Timeframe: 18 months
Variation of the proportion of CD8+ subpopulations between both patient groups
Timeframe: 18 months
Variation of the proportion of TH1 subpopulations between both patient groups
Timeframe: 18 months
Variation of the proportion of TH2 subpopulations between both patient groups
Timeframe: 18 months
Variation of the proportion of TH17 subpopulations between both patient groups
Timeframe: 18 months
Variation of the proportion of Treg subpopulations between both patient groups
Timeframe: 18 months
Variation of the proportion of ILC 1 subpopulations between both patient groups
Timeframe: 18 months
Amandine Dernoncourt, DR
Variation of the proportion of ILC 2 subpopulations between both patient groups
Timeframe: 18 months
Variation of the proportion of ILC 3 subpopulations between both patient groups
Timeframe: 18 months
Variation of the proportion of TNFα concentrations between both patient groups
Timeframe: 18 months
Variation of the proportion of IFN gamma concentrations between both patient groups
Timeframe: 18 months
Variation of the proportion of TGF-β concentrations between both patient groups
Timeframe: 18 months
Variation of the proportion of IL-10 concentrations between both patient groups
Timeframe: 18 months
Variation of the proportion of IL-17 concentrations between both patient groups
Timeframe: 18 months